Delving into the Latest Updates on Autologous NK cell(Guangzhou DoublleBioproduct) with Synapse

Overview

Basic Info

Drug Type

Natural Killer Cell Therapies

Synonyms

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Advanced gastric carcinomaColorectal CancerStomach Cancer

Inactive Indication-

Originator Organization

Guangzhou Doublle Bioproduct Co., Ltd.

Active Organization

Guangzhou Doublle Bioproduct Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价 E10H 在晚期消化道癌患者中静脉输注给药、剂量递增的安全性和耐受性。次要目的： 1) 评价 E10H 在晚期消化道癌患者中静脉输注给药的初步疗效。 2) 评价 E10H 在晚期消化道癌患者中静脉输注给药的药代动力学/药效动力学（PK/PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of E10H administered by intravenous infusion and dose escalation in patients with advanced gastrointestinal cancer. Secondary objectives: 1) To evaluate the preliminary efficacy of E10H administered by intravenous infusion in patients with advanced gastrointestinal cancer. 2) To evaluate the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of E10H administered by intravenous infusion in patients with advanced gastrointestinal cancer.

Start Date18 Nov 2022

Sponsor / Collaborator

Guangzhou Doublle Bioproduct Co., Ltd.

JPRN-UMIN000014072

/ RecruitingPhase 1/2IIT

A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphoma - A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with B-cell lymphoma

Start Date01 Jun 2014

Sponsor / Collaborator-

100 Clinical Results associated with Autologous NK cell(Guangzhou DoublleBioproduct)

Login to view more data

100 Translational Medicine associated with Autologous NK cell(Guangzhou DoublleBioproduct)

Login to view more data

100 Patents (Medical) associated with Autologous NK cell(Guangzhou DoublleBioproduct)

Login to view more data

100 Deals associated with Autologous NK cell(Guangzhou DoublleBioproduct)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced gastric carcinoma	Phase 1	China	Guangzhou Doublle Bioproduct Co., Ltd.	18 Nov 2022
Colorectal Cancer	Phase 1	China	Guangzhou Doublle Bioproduct Co., Ltd.	18 Nov 2022
Stomach Cancer	Phase 1	China	Guangzhou Doublle Bioproduct Co., Ltd.	18 Nov 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2013	Phase 2	Advanced Lung Non-Small Cell Carcinoma Second line \| Third line	19	Autologous ex vivo expanded NK cell-enriched lymphocytes + Docetaxel	(drdoilcknd) = bvsgevmegf zgcztzjevu (tfwsbusbvt ) View more	-	20 May 2013
				Docetaxel	(drdoilcknd) = ehwqknzqeb zgcztzjevu (tfwsbusbvt ) View more